SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is currently trending as investors prepare for a pivotal FDA advisory committee meeting on July 29 regarding the approval of deramiocel for Duchenne muscular dystrophy. The community is heavily focused on the potential scope of the drug's label, with intense debate over whether the FDA will limit the approval to cardiomyopathy or include skeletal muscle function, while retail sentiment remains volatile due to high short interest and anticipation of significant price action.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to an expanded partnership with AT&T aimed at accelerating network optimization, alongside the company's recent strategic transition to the Nasdaq exchange. Community discussion is polarized, with bulls highlighting the technological validation and growth potential of the AT&T deal, while bears express skepticism regarding high valuations and the company's path to profitability.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp is trending following mixed sentiment regarding a retracted Kenya tender announcement and ongoing discussions about the company's Tanbreez project valuation. While some investors remain bullish on the long-term strategic importance of its heavy rare earth assets, others express frustration over share price volatility, management execution, and perceived lack of transparency.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors react to new federal executive orders aimed at accelerating domestic quantum technology leadership and secure data migration. The community is actively debating the stock's long-term potential versus concerns over cash burn rates, insider selling, and the reliability of government-linked catalysts.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending as investors debate whether the recent double-digit volatility represents a massive buying opportunity ahead of upcoming earnings or a fundamental shift in the stock's valuation. While community sentiment is heavily polarized between long-term bulls highlighting strong AI data center backlog demand and aggressive short-sellers citing supply chain concerns, the stock remains a primary focus for traders watching institutional options flow and technical support levels.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a significant share price decline, which community members largely attribute to manipulative short-selling tactics and misinterpretations of preliminary, incomplete prescription data. Despite the recent volatility, long-term investors are highlighting upcoming catalysts like the July J-code activation, European regulatory progress, and potential milestone payments as evidence that the stock remains fundamentally undervalued.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate whether the asset is finally carving out a macro bottom, fueled by technical signals like potential head-and-shoulders formations and bullish chart indicators. The community remains deeply divided, with many users highlighting increasing merchant adoption and institutional custody integration while others express frustration over stagnant price action and persistent market skepticism.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is facing significant downward pressure following leadership changes as CEO Ying Huang steps down, fueling investor uncertainty regarding strategic continuity during a critical growth phase. While some market participants see the current volatility as an overreaction to the transition and potential competitive shifts in the multiple myeloma space, others remain cautious until the company provides further clarity on its long-term commercial execution and in-vivo pipeline potential.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

The ProShares UltraShort Bloomberg Crude Oil (SCO) is actively trending as traders debate the future of oil supply disruptions in the Strait of Hormuz and the potential for a diplomatic resolution. Community sentiment is deeply divided between those betting on a sharp reversal due to de-escalation catalysts and others warning of volatility decay inherent in holding leveraged inverse ETFs over extended periods.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is surging after announcing a 53 million dollar private placement, with community sentiment split between excitement over the potential for the capital to accelerate its immunology pipeline and skepticism regarding possible dilution. Traders are actively discussing the stock's high volatility and institutional interest, while some remain cautious about the long-term impact on the share price following the recent financing news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$TLTFF a whole lotta .26c shares come free trading in July and August. That will very likely kill any buying momentum

StockTwits for iOS

Theralase Technologies Inc.

 a whole lotta .26c shares come free trading in July and August. That will very likely kill any buying momentum

Jay Cab

StockTwits Web

Eric

@PhantomZ 4.2M .26’s come free trading July 12. 6.4M .26’s come free trading Aug 12. That’s 10.6M shares in a month. These are 4 month hold expiration dates of recent private placements. If you don’t think that will be a share price drag I have a bridge to sell you. The companies would need an enormous news catalyst to overcome such supply hitting the market.

 4.2M .26’s come free trading July 12. 6.4M .26’s come free trading Aug 12. That’s 10.6M shares in a month. These are 4 month hold expiration dates of recent private placements. If you don’t think that will be a share price drag I have a bridge to sell you. The companies would need an enormous news catalyst to overcome such supply hitting the market.

@SabaiSabai most  who  bought  in  the  PP’s  did  so  to  hold  until real  gains.    Those  who  participated in  brokered  placement shorted  before and  already  covered  with  issued  shares.    Not  worried  about  those  shares.   There  will  always be a few  sellers,  but  nothing substantial IMO.

 most  who  bought  in  the  PP’s  did  so  to  hold  until real  gains.    Those  who  participated in  brokered  placement shorted  before and  already  covered  with  issued  shares.    Not  worried  about  those  shares.   There  will  always be a few  sellers,  but  nothing substantial IMO.

@PhantomZ I expect some to sell and just carry the free 5 year warrants with no acceleration to worry about. Daily volume is highly illiquid so it won’t take much to pressure the stock. It’s certainly undervalued but then this managed team is extremely hard to take seriously. The AGM transcript speaks volumes.

 I expect some to sell and just carry the free 5 year warrants with no acceleration to worry about. Daily volume is highly illiquid so it won’t take much to pressure the stock. It’s certainly undervalued but then this managed team is extremely hard to take seriously. The AGM transcript speaks volumes.

@SabaiSabai @PhantomZ where is the transcript ?

Patrick Orourke

@PatrickandFrankie @PhantomZ just pull up the YT video and read along with the transcript

 just pull up the YT video and read along with the transcript